We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Newly Published Data Shows Chronix Biomedicals’s Serum DNA Assays can Monitor Disease Activity and Treatment Response in Multiple Sclerosis

News   Apr 06, 2010

 
Newly Published Data Shows Chronix Biomedicals’s Serum DNA Assays can Monitor Disease Activity and Treatment Response in Multiple Sclerosis
 
 
 

RELATED ARTICLES

Concern Over Fake ISO 9001 Accreditation of Chinese Companies

News

A study concludes that fake ISO 9001 quality certificates are very widespread across Chinese companies and that the certification processes of the auditing companies lack credibility.

READ MORE

Altering Stathmin2 Expression Rescues Motor Neuron Growth

News

Research led by stem cell scientists at Harvard University points to a potential new biomarker and drug target for amyotrophic lateral sclerosis (ALS), a neurological disease that is difficult to diagnose and treat.

READ MORE

Blood-brain Barrier Breakdown Early Marker of Human Cognitive Dysfunction

News

Individuals with early cognitive function develop brain capillary damage and blood-brain barrier breakdown in the hippocampus, regardless of amyloid beta/tau biomarker changes.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE